Clinical trial
A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis
NCT05163886 is registered in ClinicalTrials.gov with IRulya Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis
- Lead sponsor
- IRulya Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 23, 2021
- Completion date
- May 31, 2025
- Enrollment
- 15 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.